Objective: to assess the effects of topical administration of metronidazole on fibroblast differentiation and on wound contraction during experimental secondary intention wound healing in rats. Methods: we submitted 108 rats to a circular wound on the back, 2cm in diameter, and divided them into six groups: control group, with application of saline solution on the wound and five experimental groups, divided according to the concentration of metronidazole solution used (4%, 6%, 8%, 10% and 12%). We changed the dressings daily throughout the trial period, which comprised three stages of analysis: three, seven and 14 days. We evaluated wound contraction by digital planimetry, and identified myofibroblasts and protomyofibroblasts using CD34 and α-SMA immunohistochemistry techniques. Results: wound contraction was not different between the experimental and the control groups. Protomyofibroblasts were significantly more numerous at seven days (p=0.022) in the 4%, 6% and 8% metronidazole groups. After 14 days, in the same groups, myofibroblasts predominated significantly (p=0.01). Conclusion: the topical administration of metronidazole solution in skin wounds healing by secondary intention was able to improve the differentiation of fibroblasts. The contraction phase of wound healing remained unchanged, without significant reduction of the contraction evaluated by digital planimetry. These results can be used in favor of the wound healing process.
INTRODUCTION
T he wound healing process is the subject of research for centuries, but in the last four decades, there has been intensified work on fibroplasia with interest in functional or cosmetic rehabilitation [1] [2] [3] .
After skin trauma, accidental or surgical, factors related to tissue repair are activated, evolving in stages: coagulation, inflammation, proliferation, wound contraction and remodeling. But these phases may be modified in various situations, such as when there is infection, which perpetuates the inflammatory process and causes the chronification of a skin lesion, such leg ulcers or, conversely, when using topical creams and special dressings that accelerate the process of fibroplasia, in aesthetic procedures 4 .
The phenomenon of wound contraction, that is, the relationship between wound size and reduction rate during healing, completed 100 years of its description 5 . However, the main cell responsible for this phenomenon, the myofibroblast, was only described after decades. In 1971, Gabbiani 6 observed fibroblasts present in granulation tissue that had their cytoplasm similar to those found in smooth muscle cells, thus describing the myofibroblast. In 1990, an
experimental study with open wounds in rat skin demonstrated that the myofibroblasts derived from the local fibroblasts, after developing muscle fibrils bands, called alpha smooth muscle actin (α-SMA), a characteristic that identifies the myofibroblast by immunohistochemistry 7 .
Original Article
Differentiation of myofibroblasts in wounds after topical use of metronidazole: an experimental study.
Diferenciação de miofibroblastos em feridas após uso tópico do metronidazol: estudo experimental.
Recent papers 8, 9 stated that the knowledge of the myofibroblasts' activating and blocking factors is a possible key for the treatment and control of neoplasms of stromal origin, such as sarcomas.
Topical metronidazole has been used to odor control in malignant fungating wounds.
These are elevated over the skin in a mushroomlike fashion, with large folds, similar to villi and crypts, which provide marked proliferation of anaerobic bacteria, resulting in foul odor lesions 10 .
This study aimed to evaluate, in an experimental model of wound healing by secondary intention, the influence of topical metronidazole solution at different concentrations on the amount of protomyofibroblasts and myofibroblasts and its potential role in the contraction phase of wound healing.
METHODS
The project was approved by the 
RESULTS
Regarding wound contraction, we observed that the areas decreased significantly over time in the CG (p=0.001), in EG I (p=0.001), EG II (p=0.001), EG III (p=0.001), EG IV (p=0.002) and EG V (p=0.002).
There was a progressive reduction of the wound on the third, seventh and 14th day in all groups analyzed. In the comparison between the experimental groups and the control one, there was no significant difference in the periods evaluated. When comparing groups two to two as to the presence of myofibroblasts on the 14th day, there was a significant difference (Table 5 ).
Conversely, Borden et al. 14 In our study, we observed that the wounds of the experimental and control groups had their area significantly decreased as time went by. 18, 20 . These immature myofibroblasts appear in the granulation tissue between fifth and sixth days after wound infliction 21 .
Protomyofibroblasts secrete a form of fibronectin called ED-A fibronectin, which has been deemed important for the expression of the myofibroblast phenotype in the wound 5, 20 .
The transformation of the fibroblast into protomyofibroblast seems to depend on the change in the mechanical stress of the wound as compared to the increase in stiffness of the normal skin. However, complete differentiation in myofibroblasts will only occur with the stimulation of the transforming growth factor beta (TGF-β) in the presence of ED-A fibronectin 5, 20 .
Platelet-derived growth factor (PDGF) and Tumor
Necrosis Factor-alpha ply roles on protomyofibroblast formation, but these cytokines isolated fail to induce α-SMA expression and differentiation into myofibroblast in vitro or in vivo 1,21 .
Hinz et al. 22 There are factors that inhibit the expression of α-SMA, such as the basic fibroblast growth factor (bFGF), which antagonizes TGF-β1 24 .
Interferon-γ produced by T cells suppresses expression of α-SMA, collagen deposition and contraction in animal models 25 . TGF-β3 alters α-SMA expression, but depends on the cell culture applied 26 . Interleukin-1 antagonizes TGF-β and, after this block, induces myofibroblast apoptosis 27 .
The relationship between the extracellular matrix and TGF-β determines normal scarring or a fibrosis process 21, 23 .
In our study, the experimental groups with the application of 4%, 6% and 8% metronidazole had a higher number of protomyofibroblasts in the wounds. The experimental groups with 10% and 12% presented lower density of these cells and antineoplastic therapies 2, 5, 9, 19, 30, 31 . Hinz and Gabbiani 32 stated that the myofibroblast is the main cell involved in fibrotic diseases, and the therapeutic strategy would be to interfere in the differentiation of this cell by controlling TGF-β1 and ED-A fibronectin.
There are reports that the mechanical tension in the wound extracellular matrix would be responsible for maintaining the presence of myofibroblasts 33, 34 . Considering the possible myofibroblasts precursors, Hinz 35 
